NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
Last fall, community activists voiced concerns over the roll out of studies on Descovy (TAF/FTC) as pre-exposure prophylaxis (PrEP) without adequately involving community advisors.
Long-acting injectable treatment takes another step closer to being a real-world option for people living with HIV, with new study results presented at IAS 2017.
The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become ava...
You may have heard about the "HIV cure with gene editing in animals" story. Here's some help making sense of the story, including what's true or not, and what to get excited about.
For the small percentage of HIV patients struggling with drug resistance, an expanded access program for a new injectable treatment might be the answer.
"Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial," write Anna Forbes and Marc-André LeBlanc, explaining that concern is inspired, in part, by controversies in earlier PrEP trials...
Participating in an HIV cure trial is not an isolated event, but must be seen in the "landscape of engagement" -- the range of other issues the participant may be facing, such as discrimination or a lack of stable housing. Stakeholder participation i...
Members of the U.S. House and Senate have signed on to "Dear Colleague" letters to the FDA Commissioner asking him to lift the one-year blood donor deferral policy on men who have sex with men.
What if someone could have HIV in his or her body, but the virus was incapable of causing harm? That's the tantalizing promise of a "functional cure" for HIV. A new trial will evaluate if gene therapy can achieve this goal.